litlas
ログインアカウント作成

Richard G. Langley

2001–2025 年に発表

別表記
Richard G Langley
111
論文数
23,991
被引用数
77
h 指数
104
i10 指数

被引用数

Richard G. Langley の年別被引用数1984 年: 被引用 1 件1998 年: 被引用 5 件2001 年: 被引用 2 件2002 年: 被引用 20 件2003 年: 被引用 42 件2004 年: 被引用 37 件2005 年: 被引用 51 件2006 年: 被引用 43 件2007 年: 被引用 81 件2008 年: 被引用 120 件2009 年: 被引用 155 件2010 年: 被引用 119 件2011 年: 被引用 162 件2012 年: 被引用 177 件2013 年: 被引用 190 件2014 年: 被引用 179 件2015 年: 被引用 237 件2016 年: 被引用 275 件2017 年: 被引用 386 件2018 年: 被引用 379 件2019 年: 被引用 938 件2020 年: 被引用 976 件2021 年: 被引用 824 件2022 年: 被引用 680 件2023 年: 被引用 653 件2024 年: 被引用 897 件2025 年: 被引用 456 件2026 年: 被引用 2 件1985〜1997 年は被引用が無いため表示していません1999〜2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,822 件、この内訳の 22.7%ドイツ: 引用元論文 636 件、この内訳の 7.9%イギリス: 引用元論文 624 件、この内訳の 7.8%カナダ: 引用元論文 567 件、この内訳の 7.1%イタリア: 引用元論文 499 件、この内訳の 6.2%中国: 引用元論文 422 件、この内訳の 5.3%フランス: 引用元論文 340 件、この内訳の 4.2%スイス: 引用元論文 293 件、この内訳の 3.6%スペイン: 引用元論文 284 件、この内訳の 3.5%日本: 引用元論文 268 件、この内訳の 3.3%オランダ: 引用元論文 202 件、この内訳の 2.5%デンマーク: 引用元論文 177 件、この内訳の 2.2%
0%22.7%その他 23.7%

機関

分野

  • Immunology and Microbiology53.2%
  • Medicine34.9%
  • Biochemistry, Genetics and Molecular Biology7.3%
  • Neuroscience1.6%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Engineering0.5%
  • その他1.7%

トピック

  • Psoriasis: Treatment and Pathogenesis21.4%
  • Dermatology and Skin Diseases12.2%
  • Spondyloarthritis Studies and Treatments9.9%
  • Rheumatoid Arthritis Research and Therapies4.1%
  • Asthma and respiratory diseases2.8%
  • Inflammatory Bowel Disease2%
  • その他47.6%

共著者

全論文

検索で開く
  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

    著者: Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, C.E.M. Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, C. Papavassilis - New England Journal of Medicine 2014 被引用: 1,964

  2. Bimekizumab versus Secukinumab in Plaque Psoriasis

    著者: Kristian Reich, Richard B. Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G. Langley, C. Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden, Christopher L. Cioffi, Luke Peterson, Andrew Blauvelt - New England Journal of Medicine 2021 被引用: 400

  3. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    著者: Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi - New England Journal of Medicine 2016 被引用: 838

  4. Psoriasis: epidemiology, clinical features, and quality of life

    著者: Richard G. Langley, G G Krueger, C E M Griffiths - Annals of the Rheumatic Diseases 2005 被引用: 1,107

  5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

    著者: Kristian Reich, April W. Armstrong, Richard G. Langley, Susan Flavin, B. Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt - The Lancet 2019 被引用: 376

  6. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

    著者: Kristian Reich, Kim Papp, Andrew Blauvelt, Richard G. Langley, April W. Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Haitian Wang, Christopher L. Cioffi, Veerle Vanvoorden, Mark Lebwohl - The Lancet 2021 被引用: 297

  7. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    著者: Kim Papp, Kristian Reich, Craig L. Leonardi, Leon Kircik, Sergio Chimenti, Richard G. Langley, ChiaChi Hu, Randall M. Stevens, Robert M. Day, Kenneth B. Gordon, Neil J. Korman, C.E.M. Griffiths - Journal of the American Academy of Dermatology 2015 被引用: 669

  8. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    著者: Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula - New England Journal of Medicine 2015 被引用: 806

  9. Bimekizumab versus Adalimumab in Plaque Psoriasis

    著者: Richard B. Warren, Andrew Blauvelt, Jerry Bagel, Kim Papp, Paul S. Yamauchi, April W. Armstrong, Richard G. Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher L. Cioffi, Luke Peterson, Nancy Cross, Kristian Reich - New England Journal of Medicine 2021 被引用: 238

  10. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

    著者: Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich - The Lancet 2008 被引用: 1,350

  11. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

    著者: Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin, Michael Song, B. Randazzo, Yasmine Wasfi, Jingzhi Jiang, S. Li, L. Puig - British Journal of Dermatology 2017 被引用: 339

  12. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

    著者: Kim Papp, Alan Menter, Mai Abe, Boni E. Elewski, Steven R. Feldman, Alice B. Gottlieb, Richard G. Langley, Thomas A. Luger, Diamant Thaçi, M. Buonanno, Pankaj Gupta, James Proulx, Shu-Ping Lan, Robert Wołk, the OPT Pivotal 1 and OPT Pivotal 2 investigators - British Journal of Dermatology 2015 被引用: 322

  13. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

    著者: Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham, Kim Papp, Sandra Philipp, Jashin J. Wu, Atsuyuki Igarashi, Mary Flack, Ziqian Geng, Tianshuang Wu, Anne Camez, David Williams, Richard G. Langley - JAMA Dermatology 2020 被引用: 216

  14. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

    著者: Andrew Blauvelt, Richard G. Langley, J.‐P. Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew Pink, Ketty Peris, Stine Fangel, Le Gjerum, Joshua Corriveau, Hidehisa Saeki, Richard B. Warren, Eric L. Simpson, Kristian Reich - Journal of the American Academy of Dermatology 2022 被引用: 75

  15. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

    著者: Kim Papp, Kristian Reich, C. Paul, Andrew Blauvelt, Wojciech Baran, Chantal Bolduc, D. Toth, Richard G. Langley, Jennifer Clay Cather, Alice B. Gottlieb, Diamant Thaçi, James G. Krueger, Chris B. Russell, C.E. Milmont, Jing Li, Paul Klekotka, Greg Kricorian, Ajay Nirula - British Journal of Dermatology 2016 被引用: 459

  16. Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities

    著者: Alan Menter, Gerald G. Krueger, So Yeon Paek, Darío Kivelevitch, Iannis E. Adamopoulos, Richard G. Langley - Dermatology and Therapy 2021 被引用: 108

  17. Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*

    著者: Kenneth B. Gordon, Mark Lebwohl, Kim Papp, H. Bachelez, Jashin J. Wu, Richard G. Langley, Andrew Blauvelt, Beth Kaplan, Megha Shah, Yiwei Zhao, Ranjeeta Sinvhal, Kristian Reich - British Journal of Dermatology 2021 被引用: 99

  18. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

    著者: Andrew Blauvelt, Kim Papp, Alice B. Gottlieb, Abel Jarell, Kristian Reich, Catherine Maari, Kenneth B. Gordon, Laura K. Ferris, Richard G. Langley, Yayoi Tada, Renata Gontijo Lima, Hany Elmaraghy, Gaia Gallo, L. Renda, S‐M. Park, Russel Burge, Jerry Bagel, the IXORA‐R Study Group, Ronald Vender, Mark Lomaga, Isabelle Delorme, Chih-ho Hong, Richard L. Langley, Lorne Albrecht, Lyn Guenther, Catherine Maari, Kim Papp, Kamal Ohson, Kirk Barber, Charles Lynde, Aditya Gupta, Leslie Rosoph, Jean‐Sébastien Gauthier, Melinda Gooderham, Norman Wasel, Mani Raman, Marni Wiseman, David Greenstein, Abel Jarell, C. A. L. Moon, Lani Clark, S. Jazayeri, Michael Bukhalo, Angela Moore, Tiffani K. Hamilton, Aron Gewirtzman, Lydie Hazan, Jeffrey Crowley, Craig Teller, Matthew Zirwas, Stacy Smith, Mark Lee, Stephen K. Tyring, Patricia Lee, Sunil Dhawan, Craig L. Leonardi, Amarilis Perez‐De Jesus, Wendy McFalda, Ellen Frankel, Paul S. Yamauchi, Scott Fretzin, Rocco Serrao, Todd Schlesinger, Scott Gottlieb, Peter Jenkin, Rola Gharib, Steven A. Davis, Navid Nami, Zoe Diana Draelos, Lloyd Godwin, Cindy E. Owen, Megan N. Landis, William Abramovits, Samuel Sanchez‐Rivera, Abby Van Voorhees, David Fivenson, Francisco A. Kerdel, Seth Forman, Jeffrey S. Weinberg, José González-Chávez, Brent Boyce, Linda Stein‐Gold, Charles P. Hudson, Constance Brown, James Coggi, Christina Feser, Rion Forconi, Sandra Johnson, Mark McCune, Lawrence Green, Vandana Madkan, Dana Maxwell Shipp, Kenneth B. Gordon, Jill Waibel, Oscar Soto‐Raices, Jennifer Cather, Scott Miller, John P. Scott, Douglas Young, Jessica Kaffenberger ほか 42 名 - British Journal of Dermatology 2019 被引用: 172

  19. The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials

    著者: Richard G. Langley, Steven R. Feldman, Judit Nyirady, Peter van de Kerkhof, C. Papavassilis - Journal of Dermatological Treatment 2013 被引用: 261

  20. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

    著者: Kim Papp, Alan Menter, Bruce Strober, Richard G. Langley, M. Buonanno, Robert Wołk, Pankaj Gupta, S. Krishnaswami, Huaming Tan, Jane Harness - British Journal of Dermatology 2012 被引用: 336

  21. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

    著者: Mark Lebwohl, H. Bachelez, Jonathan Barker, Giampiero Girolomoni, Arthur Kavanaugh, Richard G. Langley, C. Paul, L. Puig, Kristian Reich, P.C.M. van de Kerkhof - Journal of the American Academy of Dermatology 2014 被引用: 511

  22. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    著者: Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp - Journal of the American Academy of Dermatology 2007 被引用: 883

  23. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

    著者: Richard G. Langley, Steven R. Feldman, Chenglong Han, Brad Schenkel, Philippe Szapary, Ming-Chun Hsu, Jean-Paul Ortonne, Kenneth B. Gordon, Alexa B. Kimball - Journal of the American Academy of Dermatology 2010 被引用: 216

  24. A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

    著者: Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, C.E.M. Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp, the IXORA‐R Study Group - British Journal of Dermatology 2020 被引用: 117